

FOI 3136

12<sup>th</sup> June 2025

### FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

I would be grateful if you could tell me how many patients were treated by individual drug for Crohn’s Disease, ulcerative colitis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis for the three-month period specified within the question.

I have provided a grid of drug names and disease names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

How many patients were treated with the following drugs for the following diseases from the start of Jan 2025 to the end of Mar 2025?

Please use the latest available 3 months if Jan to Mar is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

#### Response:

| Drug Name                | Plaque psoriasis | Crohn’s Disease | Ulcerative colitis | Psoriatic arthritis | Ankylosing spondylitis (inc. axial spondylitis) | Rheumatoid arthritis |
|--------------------------|------------------|-----------------|--------------------|---------------------|---|----------------------|
| Adalimumab               | 268              | 134             | 63                 | 228                 | 208   | 180                  |
| Apremilast               | 0                |                 |                    | 0                   |   |                      |
| Bimekizumab              | 15               |                 |                    | 1                   | 1   |                      |
| Brodalumab               | 6                |                 |                    |                     |   |                      |
| Certolizumab Pegol       | 5                |                 |                    | 32                  | 27  | 19                   |
| Deucravacitinib          | 0                |                 |                    |                     |   |                      |
| Etanercept               | 2                |                 |                    | 67                  | 39  | 120                  |
| Guselkumab               | 65               |                 |                    | 15                  |   |                      |
| Infliximab (Remicade)    | 0                | 0               | 0                  | 0                   | 0   | 0                    |
| Infliximab (Biosimilars) | 3                | 49              | 64                 | 10                  | 7   | 10                   |
| Ixekizumab               | 116              |                 |                    | 43                  | 16  |                      |

|               |    |    |    |    |    |    |
|---------------|----|----|----|----|----|----|
| Risankizumab  | 96 | 2  | 1  | 4  |    |    |
| Secukinumab   | 32 |    |    | 93 | 61 |    |
| Tildrakizumab | 5  |    |    |    |    |    |
| Ustekinumab   | 24 | 69 | 34 | 1  |    |    |
| Upadacitinib  |    | 14 | 13 | 6  | 7  | 20 |
| Vedolizumab   |    | 53 | 58 |    |    |    |
| Filgotinib    |    |    | 0  |    |    | 0  |
| Golimumab     |    |    | 1  | 24 | 32 | 16 |
| Mirikizumab   |    |    | 1  |    |    |    |
| Ozanimod      |    |    | 0  |    |    |    |
| Etrasimod     |    |    | 0  |    |    |    |
| Tofacitinib   |    |    | 3  | 3  | 0  | 5  |
| Baricitinib   |    |    |    |    |    | 41 |
| Rituximab     |    |    |    |    |    | 99 |
| Sarilumab     |    |    |    |    |    | 20 |
| Tocilizumab   |    |    |    |    |    | 40 |

Email: [Foi.Team@Southerntrust.hscni.net](mailto:Foi.Team@Southerntrust.hscni.net)